Tumour Models Summit Nordics

Welcome to the first ever Tumour Models Summit Nordics. This April, the critically acclaimed Tumour Models series will be coming to the Nordics for the first time ever, uniting more than seventy pharma, biotech, and research leaders across the Nordic biotech landscape.

The inherent heterogeneity of cancer – both inter-patient and intra-tumoral – remains a significant challenge in cancer modelling. With only 5% of cancer drugs successfully advancing to clinical trials, there is a critical need for more accurate and predictive models to guide therapeutic development.

To serve this need, the Tumour Models Summit Nordics will unite pharma, biotech, and research leaders from across the thriving Nordic biotech ecosystem to tackle this challenge head-on for the first time ever. Experts working across preclinical, translational, discovery, toxicity, and biology will gather in Stockholm this April to collaborate and overcome the industry’s biggest obstacles for 2025. As the region’s only industry-led event of its kind, this summit provides a rare opportunity to connect with top experts from these developmental areas.

Gain insights into the cutting-edge innovation in in vivo and in vitro tumour modelling, discover strategies to de-risk your studies, and learn how to refine your drug development pipeline.

Key highlights of the agenda include:

• Leveraging cutting-edge 3D in vitro models with Roche
• Target/receptor axis modelling with Anocca
• Humanised mouse models with BioInvent
• Advanced omics data with Curacell
• Treating solid tumours with Hemispherian

Previous attendees of the Tumour Models Summits in Boston, San Francisco, and London have celebrated the summit’s range, relevance, and focus with comments such as, “This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world” (Roche), and “The conference exceeded my expectations. The talks were very relevant to my day-to-day work as in vivo scientist in a cell therapy company. I enjoyed the networking; attendees were very approachable” (Arsenal Biosciences).

Find out why they said this and secure your free pass to join us to engage with decision-makers, explore groundbreaking solutions, and accelerate the path from lab to patient in today’s rapidly evolving landscape.

We’ll see you there!

Get your free pass now whilst still available: https://ter.li/qdc9zo